BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
Noteworthy Thursday Option Activity: HIBB, NTGR, BBIO
Relative Strength Alert For BridgeBio Pharma
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo,...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Notable Two Hundred Day Moving Average Cross - BBIO
Investors Bag BBIO Even Cheaper Than Its Secondary Stock Offering
Interesting BBIO Put And Call Options For April 26th
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company...
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company...
Noteworthy Monday Option Activity: MU, BBIO, BURL
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in...
BridgeBio Pharma GAAP EPS of -$0.96 misses by $0.04, revenue of $1.75M misses by $2.04M (NASDAQ:BBIO)
BridgeBio Pharma's Q4 financial results fall short with a GAAP EPS miss of $0.04 and a revenue miss of $2.04M.
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin amyloid cardiomyopathy...
Alnylam stock falls on Q4 topline miss (NASDAQ:ALNY)
Alnylam Pharmaceuticals (ALNY) reports lower-than-expected revenue for Q4 2023 and delays key Phase 3 readout due to changes in data analysis. Read more here.
BridgeBio grants Japanese rights to Kyowa Kirin for dwarfism drug (NASDAQ:BBIO)
BridgeBio (BBIO) has granted an exclusive license to Kyowa Kirin for the Japanese development and commercialization rights to its dwarfism drug infigratinib. Read more here.
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting...
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global...
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a...
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry.
March 8th Options Now Available For BridgeBio Pharma (BBIO)
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.
BridgeBio Pharma in royalty deal for lead drug (NASDAQ:BBIO)
BridgeBio Pharma (BBIO) secures $500M through a royalty agreement with Blue Owl (OWL) and the Canada Pension Plan for its lead candidate acoramidis. Read more here.